EGFR and lung adenocarcinoma: A recently published retrospective study, which evaluated the type and frequency of SREs in patients with EGFR-mutated lung adenocarcinoma and bone metastases (n = 274, of which 148 treated with EGFR-TKI), showed that one-third of these patients developed their first SRE before start of EGFR-TKI treatment, the other two-third of the patients developed SREs in the first year of EGFR-TKI treatment [49].